Nilotinib has shown significant benefits in the treatment of CML, particularly in patients who do not respond to first-line treatments. Some of the key benefits include:
Improved survival rates and progression-free survival Higher rates of complete cytogenetic response (CCyR) Better tolerability and fewer severe side effects compared to first-generation TKIs
